12/30
01:19 pm
ikna
Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade [Yahoo! Finance]
Neutral
Report
Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade [Yahoo! Finance]
12/23
08:11 pm
ikna
Ikena Oncology, Inc. (NASDAQ: IKNA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $2.00 price target on the stock.
High
Report
Ikena Oncology, Inc. (NASDAQ: IKNA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $2.00 price target on the stock.
12/23
08:42 am
ikna
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement [Yahoo! Finance]
Medium
Report
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement [Yahoo! Finance]
12/23
08:30 am
ikna
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
Medium
Report
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
11/11
08:09 am
ikna
Ikena Oncology, Inc. (NASDAQ: IKNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Low
Report
Ikena Oncology, Inc. (NASDAQ: IKNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
11/9
10:11 am
ikna
Ikena Oncology Third Quarter 2024 Earnings: US$0.21 loss per share (vs US$0.40 loss in 3Q 2023) [Yahoo! Finance]
Low
Report
Ikena Oncology Third Quarter 2024 Earnings: US$0.21 loss per share (vs US$0.40 loss in 3Q 2023) [Yahoo! Finance]
11/7
08:30 am
ikna
Ikena Oncology Reports Third Quarter 2024 Financial Results
Low
Report
Ikena Oncology Reports Third Quarter 2024 Financial Results